TrialJournal of Crohn's & colitis2024

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

Marc Ferrante et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.